Pfizer calls out 'impermissible fishing expedition' in fight over Enbrel biosimilar

Pfizer calls out ‘impermissible fishing expedition’ in fight over Enbrel biosimilar

Intellectual Property 2024-06-05 10:17 pm By Andy Sidler | Melbourne

Please login to bookmark

Drug giant Pfizer has blasted Samsung Bioepis’ “fishing expedition” in its suit alleging infringement of the patent for its blockbuster arthritis drug Enbrel, telling the court the Korean biotech should not be allowed to dig for new grounds of invalidity.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

error: The content is secured.

For information on rights and reprints, contact subscriptions@lawyerly.com.au